Lenvatinib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer
Trial Timeline
Mar 1, 2010 → Oct 1, 2015
NCT ID
NCT01111461About Lenvatinib
Lenvatinib is a phase 2 stage product being developed by Eisai for Endometrial Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01111461. Target conditions include Endometrial Cancer.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Cancer were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03533361 | Pre-clinical | Completed |
| NCT02211222 | Pre-clinical | Completed |
| NCT05901194 | Phase 1/2 | Active |
| NCT06138769 | Phase 2 | Active |
| NCT05171335 | Phase 2 | Recruiting |
| NCT05103904 | Phase 2 | Recruiting |
| NCT04321954 | Phase 2 | Active |
| NCT04297254 | Approved | Completed |
| NCT04447755 | Phase 2 | Completed |
| NCT04008082 | Pre-clinical | Completed |
| NCT03506048 | Phase 2 | Terminated |
| NCT03009292 | Phase 1 | Completed |
| NCT03663114 | Pre-clinical | Completed |
| NCT02846766 | Phase 2 | Withdrawn |
| NCT03433703 | Phase 2 | Terminated |
| NCT03573960 | Approved | Completed |
| NCT03168074 | Phase 2 | UNKNOWN |
| NCT02953743 | Phase 1 | Completed |
| NCT02780310 | Phase 2 | Active |
| NCT02579616 | Phase 2 | Completed |
Competing Products
20 competing products in Endometrial Cancer